MPPE1 and neoplasm: The rapid ADA induction and loss of drug activity in the cDC1-targeted Ab-IFN fusions highlight the potential complexity in developing Ab-based therapeutics to enhance cDC1 DC tumor antigen immunogenicity due to the biological role of cDC1s and the risk of inducing ADA.